-
16160-1A pivotal molecule in the Krebs cycle, in the synthesis of fatty acids, and in isoprenoid-based protein modifications serves as an intermediate in oxidation of fatty acids and amino acids an essential cofactor or substrate for acetyltransferases
-
16160-10A pivotal molecule in the Krebs cycle, in the synthesis of fatty acids, and in isoprenoid-based protein modifications serves as an intermediate in oxidation of fatty acids and amino acids an essential cofactor or substrate for acetyltransferases
-
16160-25A pivotal molecule in the Krebs cycle, in the synthesis of fatty acids, and in isoprenoid-based protein modifications serves as an intermediate in oxidation of fatty acids and amino acids an essential cofactor or substrate for acetyltransferases
-
16160-5A pivotal molecule in the Krebs cycle, in the synthesis of fatty acids, and in isoprenoid-based protein modifications serves as an intermediate in oxidation of fatty acids and amino acids an essential cofactor or substrate for acetyltransferases
-
10007686-1A potent, semi-synthetic LXR agonist derived from extracts of the mayapple induces the expression of the ABCA1 reverse cholesterol transporter to increase the efflux of cholesterol from enterocytes and thus inhibits the overall absorption of
-
10007686-10A potent, semi-synthetic LXR agonist derived from extracts of the mayapple induces the expression of the ABCA1 reverse cholesterol transporter to increase the efflux of cholesterol from enterocytes and thus inhibits the overall absorption of
-
10007686-5A potent, semi-synthetic LXR agonist derived from extracts of the mayapple induces the expression of the ABCA1 reverse cholesterol transporter to increase the efflux of cholesterol from enterocytes and thus inhibits the overall absorption of
-
10007686-50A potent, semi-synthetic LXR agonist derived from extracts of the mayapple induces the expression of the ABCA1 reverse cholesterol transporter to increase the efflux of cholesterol from enterocytes and thus inhibits the overall absorption of
-
A0819-1 kgNSAID and COX-1/2 inhibitor used to decrease inflammation. It inhibits platelet aggregation and prolongs bleeding time by decreasing levels of thromboxane A2. Chronic administration decreases risk of cancer and cardiovascular events.
-
A0819-500 gNSAID and COX-1/2 inhibitor used to decrease inflammation. It inhibits platelet aggregation and prolongs bleeding time by decreasing levels of thromboxane A2. Chronic administration decreases risk of cancer and cardiovascular events.
-
14003-1A glutamine analog that irreversibly inhibits glutamine-dependent amidotransferases involved in nucleotide and amino acid biosynthesis (Kis = 10 and 560 &muM for anthranilate synthase and glutamate synthase, respectively) reversibly inhibits
-
14003-10A glutamine analog that irreversibly inhibits glutamine-dependent amidotransferases involved in nucleotide and amino acid biosynthesis (Kis = 10 and 560 &muM for anthranilate synthase and glutamate synthase, respectively) reversibly inhibits